GlassScriptPhysician profile
Julia Escandon Brehm
NPI 1952861627
$6,863.70
in general payments reported to CMS, 2019-2025
27 companies · $3,141 in 2025
The $3,141 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $105 · 2021: $193 · 2022: $377 · 2023: $1,003 · 2024: $1,731 · 2025: $3,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,486 · Education: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,486.16 |
| Education | $388.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,077.27 | 2020-2025 | |
| Pfizer INC. | $883.16 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $696.81 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $688.90 | 2022-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $630.07 | 2024-2025 | Tremfya |
| Genzyme Corporation | $598.40 | 2021-2025 | |
| Galderma Laboratories, L.P. | $344.13 | 2022-2025 | Dysport |
| Novartis Pharmaceuticals Corporation | $258.97 | 2024-2025 | |
| Ucb, INC. | $224.69 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $176.15 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $175.62 | 2022-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $162.85 | 2024-2025 | |
| Allergan, INC. | $149.63 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $148.91 | 2023-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $93.47 | 2024 | Adbry |
| Almirall LLC | $79.83 | 2024-2025 | Seysara, Klisyri |
| Botanix Sb INC | $73.42 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $73.02 | 2024-2025 | Ycanth |
| Lnhc, INC | $64.66 | 2025 | Zelsuvmi |
| Dermavant Sciences, INC. | $52.53 | 2024 | Vtama |
| Strata Skin Sciences, INC. | $27.57 | 2025 | Xtrac |
| Hill Dermaceuticals, INC. | $26.50 | 2025 | Tolak |
| Biofrontera INC. | $22.33 | 2025 | Ameluz |
| Arcutis Biotherapeutics, INC. | $20.17 | 2025 | Zoryve |
| Organon LLC | $14.65 | 2025 | Vtama |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Escandon Brehm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.